½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1594991

¼¼°èÀÇ OTC(Over The Counter) °Ë»ç ½ÃÀå

Over The Counter (OTC) Testing

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Industry Analysts, Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 89 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ OTC(Over The Counter) °Ë»ç ½ÃÀåÀº 2030³â±îÁö 436¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â¿¡ 233¾ï ´Þ·¯·Î ÃßÁ¤µÈ ¼¼°èÀÇ OTC(Over The Counter) °Ë»ç ½ÃÀåÀº 2030³â¿¡´Â 436¾ï ´Þ·¯¿¡ ´ÞÇϸç, ºÐ¼® ±â°£ÀÎ 2023-2030³âÀÇ CAGRÀº 9.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ±Û·çÄÚ¿À½º ¸ð´ÏÅ͸µ °Ë»ç´Â CAGR 8.2%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 117¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àӽš¤ºÒÀÓ °Ë»ç ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 9.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 63¾ï ´Þ·¯, Áß±¹Àº CAGR 8.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ OTC(Over The Counter) °Ë»ç ½ÃÀåÀº 2023³â¿¡ 63¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2023-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 8.8%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â 68¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 7.8%¿Í 7.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 6.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ OTC(Over The Counter) °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¾×¼¼½º °¡´ÉÇÑ ÇコÄɾ OTC(Over The Counter) °Ë»ç°¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â?

OTC(Over The Counter) °Ë»ç´Â °³ÀÎÀÌ Áý¿¡¼­ Æí¸®ÇÏ°Ô °Ç°­ °Ë»ç¸¦ Á÷Á¢ ¹ÞÀ» ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇÔÀ¸·Î½á ÇコÄɾ Çõ¸íÀ» ÀÏÀ¸Ä×À¸¸ç, OTC °Ë»ç´Â Ç÷´ç ¹× ÄÝ·¹½ºÅ×·Ñ ¼öÄ¡ºÎÅÍ ÀÓ½Å, ºÒÀÓ, °¨¿°¿¡ À̸£±â±îÁö ´Ù¾çÇÑ °Ç°­ ÁöÇ¥¸¦ ÀÇ»çÀÇ Áø·á³ª ó¹æÀü ¾øÀ̵µ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇコÄɾ ȯÀÚ Áß½ÉÀÇ Á¢±Ù¼º ³ôÀº ÀÇ·á·Î ÀüȯµÇ°í ÀÖ´Â °¡¿îµ¥, OTC °Ë»ç´Â Àû±ØÀûÀÎ ÇコÄɾ ¿øÇÏ´Â °³Àο¡°Ô ÇʼöÀûÀÎ ÅøÀÌ µÇ°í ÀÖ½À´Ï´Ù. OTC °Ë»ç´Â ½Ã°£, ºñ¿ë, Á¢±Ù¼º µî ±âÁ¸ °Ë»ç½Ç °Ë»ç¿Í °ü·ÃµÈ À庮À» Á¦°ÅÇÏ¿© º¸´Ù Á¾ÇÕÀûÀÎ ÇコÄɾ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

OTC °Ë»ç´Â Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀÌ È¿°úÀûÀÎ Ä¡·á¿¡ ÇʼöÀûÀÎ ´ç´¢º´°ú °°Àº ¸¸¼ºÁúȯ °ü¸®¿¡ ƯÈ÷ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. °¡Àå ³Î¸® »ç¿ëµÇ´Â OTC °Ë»ç Áß ÇϳªÀÎ Ç÷´ç ÃøÁ¤±â´Â ´ç´¢º´ ȯÀÚ°¡ ¸ÅÀÏ Ç÷´ç ¼öÄ¡¸¦ ÃßÀûÇÏ¿© ¾à¹° °ü¸®¿Í »ýÈ°½À°ü Á¶Àý¿¡ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î Áý¿¡¼­ ÇÒ ¼ö ÀÖ´Â ÄÝ·¹½ºÅ×·Ñ °Ë»ç´Â ½ÉÇ÷°ü ÁúȯÀÇ À§ÇèÀÌ ÀÖ´Â »ç¶÷µéÀÌ ÀÚ½ÅÀÇ °Ç°­ »óŸ¦ ¸ð´ÏÅ͸µÇÏ°í ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î »ýÈ°½À°üÀ» ¹Ù²Ü ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. Àα¸ °í·ÉÈ­¿Í ¸¸¼ºÁúȯ Áõ°¡·Î ÀÎÇØ OTC °Ë»ç´Â Á¤±âÀûÀÎ °Ç°­ ¸ð´ÏÅ͸µÀ» À§ÇÑ ½Ç¿ëÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ¿© Á¶±â ¹ß°ß°ú °³ÀÔÀ» Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù¼ºÀº °³ÀÎÀÇ °Ç°­ °á°ú¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÀÏ»óÀûÀÎ ¸ð´ÏÅ͸µ¿¡ ÇÊ¿äÇÑ ÀÚ¿øÀ» ÁÙ¿© ÀÇ·á ½Ã¼³ÀÇ ºÎ´ãÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ OTC °Ë»ç´Â °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ ¸¹Àº »ç¶÷µéÀÌ ÀÚ½ÅÀÇ °Ç°­À» °ü¸®ÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» ã°í ÀÖ´Â °¡¿îµ¥, OTC °Ë»ç´Â Á¡Á¡ ´õ ¸¹Àº »ç¶÷µéÀÇ ÁöÁö¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. °¡Á· °èȹÀ» ¼¼¿ì´Â ºÎºÎ¸¦ À§ÇÑ ºÒÀÓ °Ë»çºÎÅÍ °¡Á··Â°ú À¯ÀüÀû ¼ÒÀÎÀ» ÆľÇÇÒ ¼ö ÀÖ´Â À¯ÀüÀÚ °Ë»ç Å°Æ®¿¡ À̸£±â±îÁö OTC °Ë»ç´Â °³ÀÎÈ­µÈ ¿¹¹æÀû ÇコÄɾ ´ëÇÑ ¼ö¿ä¸¦ ÃæÁ·½ÃÅ°°í ÀÖ½À´Ï´Ù. °Ë»ç ±â¼úÀÇ ±Þ¼ÓÇÑ ¹ßÀü°ú ÇÔ²² ½Å·ÚÇÒ ¼ö ÀÖ°í »ç¿ëÇϱ⠽¬¿î OTC °Ë»çÀÇ À¯ÇüÀÌ ´Ã¾î³ª¸é¼­ ´Ù¾çÇÑ ¿ä±¸¸¦ ÃæÁ·½ÃÅ°°í °³ÀÎÀÌ ÀÚ½ÅÀÇ °Ç°­¿¡ ´ëÇÑ Á¤º¸¸¦ Áö¼ÓÀûÀ¸·Î ÆľÇÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °³Àΰú Àû½Ã ÀÇ·á ¼­ºñ½º »çÀÌÀÇ °£±ØÀ» ¸Þ¿ö Á¶±â °³ÀÔ°ú Àû±ØÀûÀÎ ÇコÄɾ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

±â¼úÀÇ ¹ßÀüÀº ¾î¶»°Ô OTC °Ë»ç ½ÃÀåÀ» °­È­Çϴ°¡?

±â¼úÀÇ ¹ßÀüÀº OTC °Ë»ç ½ÃÀåÀÇ ¼ºÀå°ú ÁøÈ­¿¡ µµ¿òÀÌ µÇ¾î °Ë»ç¸¦ º¸´Ù Á¤È®ÇÏ°í, Àú·ÅÇÏ°í, ½±°Ô »ç¿ëÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. »ýÈ­ÇÐ ¹× ºÐÀÚ»ý¹°ÇÐÀû °Ë»çÀÇ ±â¼ú Çõ½ÅÀº OTC °Ë»çÀÇ ¹Î°¨µµ¿Í ƯÀ̵µ¸¦ Å©°Ô Çâ»ó½ÃÄÑ »ç¿ëÀÚ¿¡°Ô ½ÇÇè½Ç ±â¹Ý °Ë»ç¿¡ ÇÊÀûÇÏ´Â ½Å·ÚÇÒ ¼ö ÀÖ´Â °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î Ãø¸é È帧 ¹× ¸é¿ª ºÐ¼® ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÓ½Å, °¨¿° ¹× ¾à¹° »ç¿ë°ú °°Àº ½Å¼ÓÇÑ °Ë»ç°¡ Çâ»óµÇ¾ú½À´Ï´Ù. ºí·çÅõ½º Ç÷´ç ÃøÁ¤±â³ª ½º¸¶Æ®Æù ¾Û°ú °°Àº µðÁöÅÐ ±â¼úÀÇ ÅëÇÕÀº »ç¿ëÀÚ°¡ ÀÚ½ÅÀÇ °Ç°­ µ¥ÀÌÅ͸¦ ÃßÀû, ÀúÀå, ºÐ¼®ÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ºÐ¼®ÇÏ¿© Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸®°í, ÇÊ¿äÇÑ °æ¿ì ÀÇ·áÁø°ú °á°ú¸¦ °øÀ¯ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

°¡Á¤¿¡¼­ÀÇ À¯ÀüÀÚ °Ë»çµµ ±â¼ú ¹ßÀüÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ´Â ºÐ¾ß Áß Çϳª·Î, Ÿ¾× »ùÇÿ¡¼­ DNA¸¦ ºÐ¼®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. °ú°Å¿¡´Â ºñ½Î°í Àü¹® °Ë»ç ±â°ü¿¡¼­¸¸ ±¸ÇÒ ¼ö ÀÖ¾ú´ø DNA °Ë»ç Å°Æ®´Â ÀÌÁ¦ OTC ä³Î¿¡¼­ ±¸ÀÔÇÒ ¼ö ÀÖÀ¸¸ç, »ç¿ëÀÚ´Â ÀÚ½ÅÀÇ °¡°è, °Ç°­ À§Çè ¹× À¯ÀüÀû ¼ÒÀο¡ ´ëÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç Å°Æ®´Â º¹ÀâÇÑ À¯ÀüÀÚ µ¥ÀÌÅ͸¦ Çؼ®Çϱâ À§ÇØ °í±Þ À¯Àüü ºÐ¼® ¾Ë°í¸®Áò°ú ½ÇÇè½Ç 󸮸¦ »ç¿ëÇÏ¿© ¼ÒºñÀÚ°¡ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â Çü½ÄÀ¸·Î Ç¥½ÃÇÕ´Ï´Ù. °³ÀÎÈ­µÈ °Ç°­ Á¤º¸¿¡ ´ëÇÑ »ç¶÷µéÀÇ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó OTC À¯ÀüÀÚ °Ë»ç´Â »ýÈ°½À°ü ¼±Åðú ¿¹¹æ ÀǷḦ À§ÇÑ ÁöħÀÌ µÇ´Â À¯ÀüÀû °Ç°­ À§ÇèÀ» ½±°Ô ÀÌÇØÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÇコÄɾîÀÇ ºÎ»óÀ¸·Î ÀÌ·¯ÇÑ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ÀÌ´Â OTC °Ë»ç ±â¼úÀÇ Çõ½ÅÀ» Áö¿øÇÏ°í ÀÖ½À´Ï´Ù.

¿ø°ÝÀÇ·á¿Í µðÁöÅÐ °Ç°­ Ç÷§ÆûÀº °¡Á¤³» °Ë»ç¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¸¦ ¿¬°áÇÏ´Â »ýÅ°踦 ±¸ÃàÇÔÀ¸·Î½á OTC °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ°í ÀÖ½À´Ï´Ù. ¸¹Àº µðÁöÅÐ °Ç°­ ¾ÛÀº OTC °Ë»ç Àåºñ¿Í ȣȯµÇ¸ç, »ç¿ëÀÚ´Â ÀÇ·á Àü¹®°¡¿Í ¿ø°ÝÀ¸·Î »ó´ãÇϰųª °Ë»ç °á°ú¿¡ µû¸¥ ÁöħÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ OTC °Ë»ç¿Í ¿ø°ÝÀÇ·áÀÇ ÅëÇÕÀ¸·Î »ç¿ëÀÚ´Â Áý¿¡¼­ °Ë»çÇÏ°í ¿Â¶óÀÎÀ¸·Î ÀÇ»ç¿Í »ó´ãÇÏ´Â ¿Ïº®ÇÑ °æÇèÀ» ´Ü½Ã°£¿¡ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î COVID-19 ÀçÅà °Ë»ç´Â Áý¿¡¼­ °Ë»ç °á°ú¸¦ ¹Þ¾Æº¼ ¼ö ÀÖÀ¸¹Ç·Î ÇÇÆøÀ» ÁÙÀÌ°í, ÇÊ¿äÇÑ °æ¿ì Àû½Ã¿¡ ÀÇ·á Á¶¾ðÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·áÀÇ µµÀÔÀÌ È®´ëµÊ¿¡ µû¶ó ÀçÅà °Ë»ç¿Í °¡»ó Áø·áÀÇ ½Ã³ÊÁö È¿°ú·Î ÀÎÇØ OTC °Ë»çÀÇ ¿¬°ü¼ºÀÌ °­È­µÇ¾î Á¢±Ù¼º°ú ÆíÀǼºÀ» ¿ì¼±½ÃÇÏ´Â Á¾ÇÕÀûÀÎ ÇコÄÉ¾î °æÇèÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

¼ÒºñÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¸¦ À§ÇÑ OTC °Ë»çÀÇ ÀåÁ¡Àº ¹«¾ùÀΰ¡?

OTC °Ë»ç´Â ¼ÒºñÀÚ¿Í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ ¸ðµÎ¿¡°Ô Å« ÀÌÁ¡À» Á¦°øÇϸç, ÀÇ·á ¼­ºñ½ºÀÇ Á¢±Ù¼º°ú È¿À²¼ºÀ» Çâ»ó½ÃÅ°´Â ±ÍÁßÇÑ ÅøÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ¿¡°Ô OTC °Ë»çÀÇ °¡Àå Å« ÀåÁ¡Àº Æí¸®ÇÔÀÔ´Ï´Ù. Áý¿¡¼­ °Ë»çÇÒ ¼ö ÀÖÀ¸¹Ç·Î OTC °Ë»ç´Â ±âÁ¸ °Ë»ç½Ç °Ë»ç¿¡ ¼ö¹ÝµÇ´Â ÀÏÁ¤, À̵¿, ´ë±â ½Ã°£ÀÌ ÇÊ¿ä ¾ø½À´Ï´Ù. ÀÌ·¯ÇÑ ÆíÀǼºÀº °Åµ¿ÀÌ ºÒÆíÇϰųª Áö¹æ¿¡ °ÅÁÖÇϰųª ¹Ù»Û ÀÏÁ¤À¸·Î ÀÎÇØ ÀÇ·á±â°üÀ» ¹æ¹®Çϱ⠾î·Á¿î »ç¶÷µé¿¡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ÀӽŠÅ×½ºÆ®, Ç÷´ç ÃøÁ¤±â, ½Å¼Ó Ç׿ø °Ë»ç µîÀÇ OTC °Ë»ç´Â ÀÌ¿ëÀÚ¿¡°Ô Áï°¢ÀûÀÎ °á°ú¸¦ Á¦°øÇÏ¿© ¾È½ÉÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. OTC °Ë»ç´Â ÀÇ·á±â°ü ¹æ¹®À» ÁÙÀÓÀ¸·Î½á ¼ÒºñÀÚ°¡ ÀÚ½ÅÀÇ °Ç°­À» °ü¸®ÇÏ°í ¾ðÁ¦µçÁö ÀÚ½ÅÀÇ °Ç°­ »óŸ¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖµµ·Ï ÇÏ¿© Àû±ØÀûÀÎ ÇコÄɾ Áö¿øÇÕ´Ï´Ù.

¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µé¿¡°Ô OTC °Ë»ç´Â Áö¼ÓÀûÀÎ °Ç°­ ¸ð´ÏÅ͸µÀ̶ó´Â Áß¿äÇÑ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù. Á¤±âÀûÀÎ Ç÷´ç, ÄÝ·¹½ºÅ×·Ñ, Ç÷¾ÐÀ» ÀçÅÿ¡¼­ °Ë»çÇÏ¿© ÇÕº´ÁõÀ» ¿¹¹æÇÏ°í Àû½Ã¿¡ ÀÇ·á °³ÀÔÀ» ÅëÇØ º¸´Ù È¿°úÀûÀ¸·Î Áúº´À» °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ÀÌ·¯ÇÑ Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ ±â´ÉÀº ÀæÀº Áø·á¼Ò ¹æ¹® ¾øÀ̵µ Æí¸®ÇÏ°Ô °æ°ú¸¦ ÃßÀûÇÒ ¼ö ÀÖÀ¸¸ç, ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÏ ¼ö ÀÖÀ¸¸ç, OTC °Ë»ç´Â °íÄÝ·¹½ºÅ×·Ñ ¹× ºñÁ¤»óÀûÀÎ Æ÷µµ´ç ¼öÄ¡¿Í °°Àº »óÅÂÀÇ Á¶±â ¹ß°ßÀ» ÃËÁøÇÏ¿© °Ç°­ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Áý¿¡¼­ ÇÒ ¼ö ÀÖ´Â ´ëÀå¾Ï ¼±º° °Ë»ç´Â Á¶±â ¹ß°ßÀ» °¡´ÉÇÏ°Ô ÇÏ°í, Á¶±â¿¡ Ä¡·á¸¦ ½ÃÀÛÇÏ¸é »ýÁ¸À²À» Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀÌó·³ OTC °Ë»ç´Â ¿¹¹æÀÇÇп¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ°í ÀÖÀ¸¸ç, °³ÀÎÀÌ ÀÚ½ÅÀÇ °Ç°­¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ôµµ OTC °Ë»ç´Â ÀÇ·á ½Ã¼³ ¼ö¿ä¸¦ ÁÙ¿© ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ Áß¿äÇÑ »ç·Ê¿¡ ÁýÁßÇÒ ¼ö ÀÖ´Ù´Â ÀÌÁ¡ÀÌ ÀÖ½À´Ï´Ù. ȯÀÚ°¡ ÀÚ½ÅÀÇ °Ç°­ »óŸ¦ ½º½º·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á OTC °Ë»ç´Â Á¤±âÀûÀÎ °Ë»ç½Ç ¹æ¹® Ƚ¼ö¸¦ ÁÙ¿© º¸´Ù ÁýÁßÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÑ È¯ÀÚ¸¦ À§ÇÑ ÀÚ¿øÀ» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÏ°í ÀÇ·á ½Ã½ºÅÛÀÇ º´¸ñ Çö»óÀ» ÃÖ¼ÒÈ­ÇÏ´Â µ¥ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ¶ÇÇÑ OTC °Ë»ç¸¦ ÅëÇØ ¼öÁýÇÑ µ¥ÀÌÅ͸¦ ÀÇ·áÁø°ú °øÀ¯ÇÔÀ¸·Î½á ¸¸¼ºÁúȯÀ» ¾Î°í Àִ ȯÀÚ¸¦ ¿ø°ÝÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀº ÀÌ µ¥ÀÌÅ͸¦ ÅëÇØ È¯ÀÚÀÇ °æ°ú¸¦ ÃßÀûÇÏ°í, Ä¡·á °èȹÀ» Á¶Á¤ÇÏ°í, ¹®Á¦°¡ ¹ß»ýÇÏ¸é ½Å¼ÓÇÏ°Ô °³ÀÔÇÒ ¼ö ÀÖÀ¸¸ç, OTC °Ë»ç´Â È¿À²ÀûÀΠȯÀÚ ¸ð´ÏÅ͸µÀ» ÃËÁøÇÏ¿© ÀÇ·á °á°ú¸¦ °³¼±ÇÏ°í ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ºÎ´ãÀ» ÁÙ¿© ÀÇ·á¿¡ ´ëÇÑ Çù·ÂÀû Á¢±ÙÀ» Áö¿øÇÕ´Ï´Ù. Áö¿øÇÕ´Ï´Ù.

¹«¾ùÀÌ OTC °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ°í Àִ°¡?

°Ç°­¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Á¢±Ù¼º ³ôÀº ÇコÄÉ¾î ¼Ö·ç¼Ç¿¡ ´ëÇÑ ´ÏÁî, °Ë»ç ±â¼úÀÇ ¹ßÀü, ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡ µîÀÇ ¿äÀÎÀÌ OTC °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. °Ç°­¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Áý¿¡¼­ °Ç°­ »óŸ¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â ÅøÀ» ã´Â »ç¶÷µéÀÌ ´Ã¾î³ª¸é¼­ OTC °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ¿À´Ã³¯ÀÇ ¼ÒºñÀÚµéÀº ÇコÄɾ Àû±ØÀûÀ̸ç, OTC Å×½ºÆ®´Â °íÇ÷¾Ð, ÄÝ·¹½ºÅ×·Ñ, Æ÷µµ´ç ¼öÄ¡¿Í °°Àº »óŸ¦ ÀÚÁÖ Àǻ縦 ¹æ¹®ÇÏÁö ¾Ê°íµµ Æí¸®ÇÏ°Ô È®ÀÎÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÀÚ°¡ °ü¸® Á¢±Ù ¹æ½ÄÀº °³ÀÎÀÌ Á¤±âÀûÀ¸·Î °Ç°­ »óŸ¦ ¸ð´ÏÅ͸µÇÏ¿© ÀáÀçÀûÀÎ ¹®Á¦¸¦ Á¶±â¿¡ ¹ß°ßÇÏ°í ´ëóÇÏ´Â ¿¹¹æÀû ÇコÄɾî Áõ°¡ Ãß¼¼¿¡ ºÎÇÕÇÕ´Ï´Ù.

°í·ÉÈ­ »çȸÀÇ µµ·¡¿Í ÇÑÁ¤µÈ ÀÚ¿ø °ü¸®¶ó´Â ¹®Á¦¿¡ Á÷¸éÇÑ Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ Á÷¸éÇÏ°í ÀÖ´Â »óȲ¿¡¼­ Á¢±Ù¼º ³ôÀº ÀÇ·á ¼Ö·ç¼ÇÀÇ Çʿ伺µµ OTC °Ë»ç ½ÃÀåÀÇ ¼ºÀå¿¡ Å« ±â¿©¸¦ ÇÏ°í ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÏ¿© ÀÇ·á ½Ã¼³ÀÇ ºÎ´ãÀ» ÁÙÀÌ°í ´õ ¸¹Àº »ç¶÷µéÀÌ °Ë»ç¿¡ Á¢±ÙÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÇ·á Á¢±Ù¼ºÀÌ Á¦ÇѵǾî Àְųª ÀÇ·á ¼­ºñ½º°¡ ÃæºÐÇÏÁö ¾ÊÀº Áö¿ª¿¡¼­´Â OTC °Ë»ç°¡ ÀÇ·á ±â°üÀ» ¹æ¹®ÇÏÁö ¾Ê°íµµ ÇʼöÀûÀÎ Áø´Ü ±â´ÉÀ» Á¦°øÇÔÀ¸·Î½á °ÝÂ÷¸¦ ÇؼÒÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·áºñ°¡ °è¼Ó »ó½ÂÇÏ´Â °¡¿îµ¥, OTC °Ë»ç´Â ƯÈ÷ ÀÇ·á ÀÎÇÁ¶ó°¡ Á¦ÇÑµÈ Áö¿ª¿¡¼­ ÀÇ·á¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Á¢±ÙÀ» Áö¿øÇÏ´Â Àú·ÅÇÑ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù.

°Ë»ç Á¤È®µµ¿Í »ç¿ë ÆíÀǼºÀÇ ±â¼ú ¹ßÀüµµ OTC °Ë»çÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­ÇÏ°í ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ºÐ¾ßÀÇ Çõ½ÅÀº OTC °Ë»çÀÇ ½Å·Ú¼º°ú ƯÀ̼ºÀ» Çâ»ó½ÃÄÑ ½ÇÇè½Ç ±â¹Ý °Ë»ç¿¡ ÇÊÀûÇÏ´Â ³ôÀº Á¤È®µµ¿Í ƯÀ̼ºÀ» È®º¸ÇÒ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. ¿¹¸¦ µé¾î ½Å¼Ó Áø´Ü °Ë»çÀÇ ¹ßÀüÀ¸·Î Áý¿¡¼­ COVID-19, µ¶°¨ µî °¨¿°º´À» °¨ÁöÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, ÀÌ¿ëÀÚ´Â ÀÚ°¡ °Ý¸® ¹× ÀÇ·á ¼­ºñ½º °áÁ¤¿¡ ÇÊ¿äÇÑ Á¤º¸¸¦ Àû½Ã¿¡ ¾òÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ¿ø°ÝÀÇ·áÀÇ ºÎ»óÀ¸·Î OTC °Ë»ç°¡ ÀÇ·á ¼­ºñ½º¿¡ ´õ¿í ÅëÇյǾú½À´Ï´Ù. ¿ø°Ý Áø·á¿Í µðÁöÅÐ °Ç°­ Ç÷§ÆûÀ» ÅëÇØ È¯ÀÚ´Â Áý¿¡¼­ °Ë»ç °á°ú¸¦ ¹ÙÅÁÀ¸·Î ÀÇ·á Á¶¾ðÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ OTC °Ë»ç¿Í ¿ø°ÝÀÇ·áÀÇ ¿øÈ°ÇÑ ÅëÇÕÀº ƯÈ÷ Á¢±ÙÇϱ⠽±°í È¿À²ÀûÀÎ ÀÇ·á ¼Ö·ç¼ÇÀ» ¿øÇϴ ȯÀڵ鿡°Ô ¸Å·ÂÀûÀÔ´Ï´Ù.

¸¶Áö¸·À¸·Î ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, °íÇ÷¾Ð°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â Á¤±âÀûÀÎ ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô ÇÏ´Â OTC °Ë»ç Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀº ºó¹øÇÑ °Ç°­ °ËÁøÀÌ ÇÊ¿äÇϹǷΠOTC °Ë»ç´Â ȯÀÚ°¡ ÀÚ½ÅÀÇ »óŸ¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ´Â Æí¸®ÇÏ°í È¿°úÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. Ç÷´ç ¸ð´ÏÅÍ, ÄÝ·¹½ºÅ×·Ñ °Ë»ç ¹× Ç÷¾Ð°è´Â ÀÌ·¯ÇÑ ¸¸¼ºÁúȯÀ» °ü¸®ÇÏ´Â »ç¶÷µéÀÌ ÀϹÝÀûÀ¸·Î »ç¿ëÇϸç ÇÊ¿ä¿¡ µû¶ó Ä¡·á °èȹÀ» Á¶Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÌ ¿©ÀüÈ÷ Áß¿äÇÑ °øÁߺ¸°Ç ¹®Á¦ÀÌ°í, OTC °Ë»ç°¡ ȯÀڵ鿡°Ô Àû±ØÀûÀÎ °Ç°­°ü¸® ¼ö´ÜÀ» Á¦°øÇÑ´Ù´Â Á¡¿¡¼­ ÀÌ·¯ÇÑ Ãß¼¼´Â ¾ÕÀ¸·Îµµ °è¼ÓµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. °Ç°­ ÀÎ½Ä Áõ°¡, Á¢±Ù¼º ³ôÀº ÀÇ·á ¼­ºñ½ºÀÇ Çʿ伺, ±â¼ú ¹ßÀü, ¸¸¼ºÁúȯÀÇ È®»ê µî ¿©·¯ ¿äÀÎÀÌ °áÇÕÇÏ¿© OTC °Ë»ç ½ÃÀåÀº Å©°Ô ¼ºÀåÇÏ°í ÀÖÀ¸¸ç, Çö´ë ÀÇ·á ¹× ¿¹¹æ ÀÇÇÐÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

°Ë»ç À¯Çü(±Û·çÄÚ¿À½º ¸ð´ÏÅ͸µ °Ë»ç, Àӽš¤ºÒÀÓ °Ë»ç, °¨¿°Áõ °Ë»ç, ÀÀ°í ¸ð´ÏÅ͸µ °Ë»ç, ¿ä°Ë»ç, ÄÝ·¹½ºÅ×·Ñ °Ë»ç, ³²¿ë ¾à¹° °Ë»ç, ±âŸ °Ë»ç À¯Çü), ±â¼ú(Ãø¹æÀ¯µ¿ ¾î¼¼ÀÌ, ¸é¿ªºÐ¼®¹ý, µö ½ºÆ½)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ ÇÕ°è 33»ç)

  • Abbott Laboratories
  • AccuBioTech
  • ACON Laboratories
  • bioLytical Laboratories
  • i-Health Lab
  • LabStyle Innovations
  • NOWDiagnostics Company
  • OraSure Technologies
  • Roche Diagnostics
  • SD Biosensor
  • Sinocare

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

  • ½ÃÀå °³¿ä
  • ÁÖ¿ä ±â¾÷
  • ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ
  • ¼¼°è ½ÃÀåÀÇ Àü¸Á

Á¦3Àå ½ÃÀå ºÐ¼®

  • ¹Ì±¹
  • ij³ª´Ù
  • ÀϺ»
  • Áß±¹
  • À¯·´
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ¿µ±¹
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ±âŸ Áö¿ª

Á¦4Àå °æÀï

KSA 24.11.26

Global Over The Counter (OTC) Testing Market to Reach US$43.6 Billion by 2030

The global market for Over The Counter (OTC) Testing estimated at US$23.3 Billion in the year 2023, is expected to reach US$43.6 Billion by 2030, growing at a CAGR of 9.3% over the analysis period 2023-2030. Glucose Monitoring Tests, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$11.7 Billion by the end of the analysis period. Growth in the Pregnancy & Fertility Tests segment is estimated at 9.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.3 Billion While China is Forecast to Grow at 8.8% CAGR

The Over The Counter (OTC) Testing market in the U.S. is estimated at US$6.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.8 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.8% and 7.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.6% CAGR.

Global Over-the-Counter (OTC) Testing Market - Key Trends & Drivers Summarized

Why Is Over-the-Counter Testing Essential for Accessible Healthcare?

Over-the-counter (OTC) testing has revolutionized healthcare by providing individuals with direct access to health tests that can be conducted privately and conveniently at home. OTC tests enable users to monitor a range of health indicators, from blood glucose and cholesterol levels to pregnancy, fertility, and infectious diseases, without requiring a doctor’s visit or prescription. As healthcare shifts toward more patient-centered and accessible care, OTC testing has become an essential tool for individuals seeking to manage their health proactively. By allowing people to test at their convenience, OTC tests eliminate barriers associated with traditional lab-based testing, such as time, cost, and accessibility issues, making healthcare more inclusive.

OTC testing has been particularly impactful for managing chronic conditions like diabetes, where continuous monitoring is crucial for effective care. Blood glucose meters, one of the most widely used OTC tests, empower diabetic patients to track their sugar levels daily, aiding in medication management and lifestyle adjustments. Similarly, at-home cholesterol tests allow individuals at risk of cardiovascular disease to monitor their health and make informed lifestyle changes. With an aging population and increasing rates of chronic illnesses, OTC testing provides a practical solution for regular health monitoring, supporting early detection and intervention. This accessibility not only improves individual health outcomes but also reduces the burden on healthcare facilities, as fewer resources are required for routine monitoring.

Additionally, OTC testing has gained traction in response to rising health awareness, as more people seek ways to take control of their wellness. From fertility tests for couples planning a family to genetic testing kits for understanding ancestry and predispositions, OTC testing meets the demand for personalized, preventive healthcare. With rapid advances in testing technology, a growing range of reliable, user-friendly OTC tests is now available, catering to diverse needs and empowering individuals to stay informed about their health. By making diagnostic testing accessible to the general public, OTC testing bridges the gap between individuals and timely healthcare, enabling early interventions and proactive health management.

How Are Technological Advancements Enhancing the OTC Testing Market?

Technological advancements have been instrumental in the growth and evolution of the OTC testing market, making tests more accurate, affordable, and user-friendly. Innovations in biochemical and molecular testing have significantly improved the sensitivity and specificity of OTC tests, providing users with reliable results that are comparable to lab-based testing. For example, advancements in lateral flow and immunoassay technologies have enhanced rapid testing for conditions like pregnancy, infectious diseases, and drug use. These tests now produce results within minutes, offering individuals fast, convenient health insights. Digital technology integration, such as Bluetooth-enabled blood glucose meters and smartphone apps, allows users to track, store, and analyze their health data, helping them make informed decisions and share results with healthcare providers as needed.

At-home genetic testing is another area that has benefited from technological advancements, making it possible to analyze DNA from a simple saliva sample. DNA testing kits, which were once expensive and only available through specialized labs, are now accessible through OTC channels and provide users with insights into their ancestry, health risks, and genetic predispositions. These kits use advanced genomic analysis algorithms and lab processing to interpret complex genetic data, presenting it in an accessible format for consumers. As people become more interested in personalized health information, OTC genetic testing offers an easy way to understand genetic health risks, which can guide lifestyle choices and preventive care. The rise of personalized healthcare has fueled demand for these tests, supporting further innovation in OTC testing technology.

Telemedicine and digital health platforms have also driven growth in the OTC testing market by creating an ecosystem that connects at-home testing with healthcare providers. Digital health apps, many of which are compatible with OTC testing devices, allow users to consult healthcare professionals remotely and receive guidance based on their test results. This integration of OTC testing with telemedicine provides a seamless experience, where users can test at home and consult a doctor online, all within a short timeframe. For example, COVID-19 home tests allow individuals to receive test results without leaving their home, reducing exposure and facilitating timely medical advice if needed. As telemedicine adoption expands, the synergy between at-home testing and virtual care strengthens the relevance of OTC tests, creating a holistic healthcare experience that prioritizes accessibility and convenience.

What Are the Benefits of OTC Testing for Consumers and Healthcare Providers?

OTC testing provides substantial benefits for both consumers and healthcare providers, making it a valuable tool in enhancing healthcare accessibility and efficiency. For consumers, the main advantage of OTC testing is convenience. By enabling people to test at home, OTC testing eliminates the need for scheduling, travel, and waiting times associated with traditional lab tests. This convenience is especially beneficial for individuals with mobility issues, those living in rural areas, or people with busy schedules who find it challenging to visit a healthcare facility. OTC tests, such as pregnancy tests, blood glucose meters, and rapid antigen tests, offer users immediate results and peace of mind. By reducing the dependency on lab visits, OTC testing empowers consumers to take control of their health and monitor their well-being at any time, supporting proactive health management.

For individuals with chronic conditions, OTC testing offers the critical benefit of continuous health monitoring. Regular at-home testing for blood glucose, cholesterol, or blood pressure enables individuals to manage their conditions more effectively, preventing complications and allowing for timely medical interventions. This continuous monitoring capability improves patient compliance, as users can conveniently track their progress without frequent clinic visits. OTC tests also enhance health outcomes by promoting early detection of conditions like high cholesterol or abnormal glucose levels, allowing individuals to make lifestyle changes or seek medical advice before conditions worsen. For example, at-home colon cancer screening tests allow for early detection, significantly improving survival rates when treatment begins early. OTC testing thus plays a crucial role in preventive care, supporting individuals in making informed decisions about their health.

Healthcare providers also benefit from OTC testing, as it helps alleviate the demand on healthcare facilities and enables providers to focus on critical cases. By empowering patients to monitor their health independently, OTC testing reduces the number of routine lab visits, freeing up resources for patients who require more intensive care. This is particularly beneficial in managing the rising demand for healthcare services and minimizing bottlenecks in the healthcare system. Additionally, data collected from OTC testing can be shared with healthcare providers, allowing for remote monitoring of patients with chronic conditions. Providers can use this data to track patient progress, make adjustments to treatment plans, and intervene promptly if issues arise. By facilitating efficient patient monitoring, OTC testing supports a collaborative approach to healthcare that enhances outcomes and reduces the burden on healthcare infrastructure.

What Is Fueling the Growth in the OTC Testing Market?

The growth in the OTC testing market is driven by factors such as rising health awareness, the need for accessible healthcare solutions, advancements in testing technology, and the increasing prevalence of chronic conditions. As health awareness continues to rise, more people are seeking tools that allow them to monitor their health from home, leading to a greater demand for OTC tests. Consumers today are more proactive in managing their health, and OTC testing offers a convenient way to check for conditions like high blood pressure, cholesterol, and glucose levels without the need for frequent doctor visits. This self-management approach aligns with the growing trend of preventive healthcare, where individuals monitor their health regularly to detect and address potential issues early.

The need for accessible healthcare solutions has also contributed significantly to the growth of the OTC testing market, as healthcare systems worldwide face challenges in meeting the demands of an aging population and managing limited resources. OTC testing provides a cost-effective solution by enabling individuals to take routine tests at home, reducing the burden on healthcare facilities and making testing accessible to a wider population. In rural or underserved areas where healthcare access is limited, OTC testing bridges the gap by providing essential diagnostic capabilities without requiring travel to a medical facility. As healthcare costs continue to rise, OTC testing offers an affordable alternative that supports broader access to healthcare, especially in regions with limited medical infrastructure.

Technological advancements in testing accuracy and ease of use have also accelerated the adoption of OTC testing. Innovations in biotechnology have improved the reliability and specificity of OTC tests, making them highly accurate and comparable to lab-based tests. For instance, advancements in rapid diagnostic tests have made it possible to detect infectious diseases like COVID-19 and influenza at home, providing users with timely information that can guide decisions on self-isolation and medical care. Additionally, the rise of telehealth has further integrated OTC testing into healthcare, as remote consultations and digital health platforms allow patients to receive medical advice based on their at-home test results. This seamless integration of OTC testing and telemedicine is especially appealing to patients seeking accessible and efficient healthcare solutions.

Finally, the increasing prevalence of chronic conditions, such as diabetes, cardiovascular disease, and high blood pressure, has fueled demand for OTC testing products that allow for regular monitoring. As chronic diseases require frequent health checks, OTC testing offers a convenient, effective solution for patients to monitor their condition consistently. Blood glucose monitors, cholesterol tests, and blood pressure cuffs are commonly used by individuals managing these chronic conditions, enabling them to adjust their treatment plans as needed. This trend is likely to continue as chronic conditions remain a significant public health issue, with OTC testing providing patients with the tools to manage their health proactively. Together, these factors—rising health awareness, the need for accessible healthcare, technological advancements, and the prevalence of chronic conditions—are driving substantial growth in the OTC testing market, making it a cornerstone of modern healthcare and preventive medicine.

SCOPE OF STUDY:

The report analyzes the Over The Counter (OTC) Testing market in terms of US$ Million by the following Technology; Test Type, and Geographic Regions/Countries:

Segments:

Test Type (Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests, Other Test Types); Technology (Lateral Flow Assays, Immunoassays, Dipsticks)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 33 Featured) -

  • Abbott Laboratories
  • AccuBioTech
  • ACON Laboratories
  • bioLytical Laboratories
  • i-Health Lab
  • LabStyle Innovations
  • NOWDiagnostics Company
  • OraSure Technologies
  • Roche Diagnostics
  • SD Biosensor
  • Sinocare

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Over The Counter (OTC) Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Demand for Home-Based Health Monitoring Drives OTC Testing Market
    • Increasing Awareness About Preventive Healthcare Sets the Stage for OTC Testing Adoption
    • Rising Adoption of Self-Testing Kits for Chronic Disease Management
    • Increasing Use of OTC Testing in Monitoring Infectious Diseases Propels Demand
    • Demand for Rapid and Accurate Results Spurs OTC Testing Solutions
    • OTC Testing as a Key Solution for Reducing Healthcare Costs
    • Use in Detecting Lifestyle Disorders Expands OTC Testing Adoption
    • Rising Demand for Genetic Testing Kits Sets the Stage for Market Growth
    • Increasing Use of OTC Testing in Monitoring Diabetes and Heart Conditions
    • Increasing Focus on Female Health Solutions Expands OTC Testing Opportunities
    • OTC Testing for Allergies and Food Intolerances Generates Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Over The Counter (OTC) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Over The Counter (OTC) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Glucose Monitoring Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Glucose Monitoring Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Glucose Monitoring Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Pregnancy & Fertility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Pregnancy & Fertility Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Pregnancy & Fertility Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Infectious Disease Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Infectious Disease Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Infectious Disease Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Coagulation Monitoring Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Coagulation Monitoring Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Coagulation Monitoring Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Urinalysis Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Urinalysis Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Urinalysis Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cholesterol Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cholesterol Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cholesterol Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Drugs-of-Abuse Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Drugs-of-Abuse Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Drugs-of-Abuse Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Dipsticks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Dipsticks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Dipsticks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Lateral Flow Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Lateral Flow Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for Lateral Flow Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 37: World Over The Counter (OTC) Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Over The Counter (OTC) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • JAPAN
    • Over The Counter (OTC) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • CHINA
    • Over The Counter (OTC) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • EUROPE
    • Over The Counter (OTC) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Over The Counter (OTC) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Over The Counter (OTC) Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • FRANCE
    • Over The Counter (OTC) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • GERMANY
    • Over The Counter (OTC) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Over The Counter (OTC) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Over The Counter (OTC) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 107: Rest of World Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of World Historic Review for Over The Counter (OTC) Testing by Test Type - Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of World 16-Year Perspective for Over The Counter (OTC) Testing by Test Type - Percentage Breakdown of Value Sales for Glucose Monitoring Tests, Pregnancy & Fertility Tests, Infectious Disease Tests, Coagulation Monitoring Tests, Urinalysis Tests, Cholesterol Tests, Drugs-of-Abuse Tests and Other Test Types for the Years 2014, 2024 & 2030
    • TABLE 110: Rest of World Recent Past, Current & Future Analysis for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of World Historic Review for Over The Counter (OTC) Testing by Technology - Immunoassays, Dipsticks and Lateral Flow Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of World 16-Year Perspective for Over The Counter (OTC) Testing by Technology - Percentage Breakdown of Value Sales for Immunoassays, Dipsticks and Lateral Flow Assays for the Years 2014, 2024 & 2030

IV. COMPETITION

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦